CADTH Canadian Drug Expert Committee recommendation. Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis.

CADTH Canadian Drug Expert Committee recommendation. indication: atopic dermatitis. Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) :

Show other versions (1)
Saved in:
Bibliographic Details
Online Access: Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2020
Edition:Final.
Series:Common drug review clinical review report.
Subjects:
Dermatitis, Atopic > drug therapy.
Antibodies, Monoclonal, Humanized > therapeutic use.
Antibodies, Monoclonal, Humanized > economics.
Cost-Benefit Analysis.
Insurance, Health, Reimbursement.
Canada.
Description
Item Description:"This recommendation supersedes the CADTH Canadian Drug Expert Committee recommendation for this drug and indication dated June 27, 2018."
Physical Description:1 online resource (1 PDF file (10 pages)).
Source of Description, Etc. Note:Description based on online resource; title from PDF title page (viewed March 18, 2021).
Funding Information Note:Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Similar Items